Equinatoxin II potentiates temozolomideand- etoposide-induced glioblastoma cell death

Current Topics in Medicinal Chemistry

Volumn 12, Issue 19, 2012, Pages 2082-2093

  Moura Neto, Vivaldo ^a   Kahn, Suzana Assad ^a   Biasoli, Deborah ^a   Garcia, Celina ^a   Geraldo, Luiz Henrique M ^a   Pontes, Bruno ^a   Sobrinho, Morgana ^a   Bon Frauches, Ana Carina ^a   Romão, Luciana ^a   Soletti, Rossana C ^a   dos Santos Assunção, Fernando ^a   Tovar Moll, Fernanda ^a,b   de Souza, Jorge Marcondes ^a   Lima, Flavia R S ^a   Anderluh, Gregor ^c,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^c NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Equinatoxin II; Etoposide; Glioblastoma; Temozolomide

Indexed keywords

CARBOPLATIN; EQUINATOXIN; ETOPOSIDE; PROTEIN KINASE B; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL COUNT; CELL DEATH; CELL SURVIVAL; CELL SUSPENSION; CELL TRANSPLANTATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; GLIOBLASTOMA; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL CULTURE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CELL CULTURE; TIME-LAPSE VIDEO MICROSCOPY; WESTERN BLOTTING;

EID: 84874928706     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212190006     Document Type: Article

References (48)

1. Aoki, T.; Hashimoto, N.; Matsutani, M., Management of glioblastoma. Expert Opin. Pharmacother., 2007, 8 (18), 3133-3146
2. Rooprai, H. K.; Vanmeter, T.; Panou, C.; Schnull, S.; Trillo-Pazos, G.; Davies, D.; Pilkington, G. J., The role of integrin receptors in aspects of glioma invasion in vitro. Int. J. Dev. Neurosci., 1999, 17 (5-6), 613-623.
3. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352 (10), 987-996.
4. Sarkaria, J. N.; Kitange, G. J.; James, C. D.; Plummer, R.; Calvert, H.; Weller, M.; Wick, W., Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res., 2008, 14 (10), 2900-2908
5. Roos, W. P.; Batista, L. F.; Naumann, S. C.; Wick, W.; Weller, M.; Menck, C. F.; Kaina, B., Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene, 2007, 26 (2), 186-197.
6. Watanabe, K.; Kanaya, H.; Fujiyama, Y.; Kim, P., Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study. Acta Neurochir. (Wien). 2002, 144 (12), 1265-1270; discussion 1270.
7. Altaner, C., Glioblastoma and stem cells. Neoplasma, 2008, 55 (5), 369-374.
8. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L., Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859), 105-111.
9. Desjardins, A.; Reardon, D. A.; Coan, A.; Marcello, J.; Herndon, J. E., 2nd; Bailey, L.; Peters, K. B.; Friedman, H. S.; Vredenburgh, J. J., Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer, 2012, 118 (5), 1302-1312.
10. Kreisl, T. N.; Kim, L.; Moore, K.; Duic, P.; Royce, C.; Stroud, I.; Garren, N.; Mackey, M.; Butman, J. A.; Camphausen, K.; Park, J.; Albert, P. S.; Fine, H. A., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol., 2009, 27 (5), 740-745.
11. Ma, J.; Pulfer, S.; Li, S.; Chu, J.; Reed, K.; Gallo, J. M., Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res., 2001, 61 (14), 5491-5498
12. Kreuzaler, P.; Watson, C. J., Killing a cancer: what are the alternatives? Nature reviews. Cancer, 2012
13. De Raedt, T.; Walton, Z.; Yecies, J. L.; Li, D.; Chen, Y.; Malone, C. F.; Maertens, O.; Jeong, S. M.; Bronson, R. T.; Lebleu, V.; Kalluri, R.; Normant, E.; Haigis, M. C.; Manning, B. D.; Wong, K. K.; Macleod, K. F.; Cichowski, K., Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell, 2011, 20 (3), 400-413.
14. Rolle, K.; Nowak, S.; Wyszko, E.; Nowak, M.; Zukiel, R.; Piestrzeniewicz, R.; Gawronska, I.; Barciszewska, M. Z.; Barciszewski, J., Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer biology & therapy, 2010, 9 (5), 396-406
15. Lima, F. R.; Kahn, S. A.; Soletti, R. C.; Biasoli, D.; Alves, T.; da Fonseca, A. C.; Garcia, C.; Romao, L.; Brito, J.; Holanda-Afonso, R.; Faria, J.; Borges, H.; Moura-Neto, V., Glioblastoma: Therapeutic challenges, what lies ahead. Biochim. Biophys. Acta, 2012, 1826 (2), 338-349.
16. Anderluh, G.; Macek, P., Cytolytic peptide and protein toxins from sea anemones (Anthozoa: Actiniaria). Toxicon, 2002, 40 (2), 111-124
17. Garcia-Saez, A. J.; Buschhorn, S. B.; Keller, H.; Anderluh, G.; Simons, K.; Schwille, P., Oligomerization and pore formation by equinatoxin II inhibit endocytosis and lead to plasma membrane reorganization. J. Biol. Chem., 2011, 286 (43), 37768-37777.
18. Soletti, R. C.; de Faria, G. P.; Vernal, J.; Terenzi, H.; Anderluh, G.; Borges, H. L.; Moura-Neto, V.; Gabilan, N. H., Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anticancer. Drugs, 2008, 19 (5), 517-525.
19. Anderluh, G.; Pungercar, J.; Strukelj, B.; Macek, P.; Gubensek, F., Cloning, sequencing, and expression of equinatoxin II. Biochem. Biophys. Res. Commun., 1996, 220 (2), 437-442.
20. Faria, J.; Romao, L.; Martins, S.; Alves, T.; Mendes, F. A.; de Faria, G. P.; Hollanda, R.; Takiya, C.; Chimelli, L.; Morandi, V.; de Souza, J. M.; Abreu, J. G.; Moura Neto, V., Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation, 2006, 74 (9-10), 562-572.
21. Lima, F. R.; Gervais, A.; Colin, C.; Izembart, M.; Neto, V. M.; Mallat, M., Regulation of microglial development: a novel role for thyroid hormone. J. Neurosci., 2001, 21 (6), 2028-2038.
22. Bernstein, C. N.; Vidrich, A., Isolation, identification, and culture of normal mouse colonic glia. Glia, 1994, 12 (2), 108-116.
23. Patru, C.; Romao, L.; Varlet, P.; Coulombel, L.; Raponi, E.; Cadusseau, J.; Renault-Mihara, F.; Thirant, C.; Leonard, N.; Berhneim, A.; Mihalescu-Maingot, M.; Haiech, J.; Bieche, I.; Moura-Neto, V.; Daumas-Duport, C.; Junier, M. P.; Chneiweiss, H., CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer, 2010, 10, 66.
24. Gardner, R. S., A sensitive colorimetric assay for mitochondrial alpha-glycerophosphate dehydrogenase. Anal. Biochem., 1974, 59 (1), 272-276.
25. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444 (7120), 756-760.
26. Rozzi, A.; Nardoni, C.; Corona, M.; Restuccia, M. R.; Fabi, A.; Bria, E.; Minniti, G.; Lanzetta, G., Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support. Care Cancer, 2011, 19 (5), 697-701
27. Einhorn, L. H.; Brames, M. J., Emetic potential of daily oral etoposide. Support. Care Cancer, 2006, 14 (12), 1262-1265.
28. Datta, S. R.; Brunet, A.; Greenberg, M. E., Cellular survival: a play in three Akts. Genes Dev., 1999, 13 (22), 2905-2927.
29. Parcellier, A.; Tintignac, L. A.; Zhuravleva, E.; Hemmings, B. A., PKB and the mitochondria: AKTing on apoptosis. Cell. Signal., 2008, 20 (1), 21-30.
30. Soletti, R. C.; Alves, T.; Vernal, J.; Terenzi, H.; Anderluh, G.; Borges, H. L.; Gabilan, N. H.; Moura-Neto, V., Inhibition of MAPK/ERK, PKC and CaMKII signaling blocks cytolysin-induced human glioma cell death. Anticancer Res., 2010, 30 (4), 1209-1215.
31. Bakrac, B.; Kladnik, A.; Macek, P.; McHaffie, G.; Werner, A.; Lakey, J. H.; Anderluh, G., A toxin-based probe reveals cytoplasmic exposure of Golgi sphingomyelin. J. Biol. Chem., 2010, 285 (29), 22186-22195
32. Lorizate, M.; Brugger, B.; Akiyama, H.; Glass, B.; Muller, B.; Anderluh, G.; Wieland, F. T.; Krausslich, H. G., Probing HIV-1 membrane liquid order by Laurdan staining reveals producer cell-dependent differences. J. Biol. Chem., 2009, 284 (33), 22238-22247.
33. Xu, J. X.; Morii, E.; Liu, Y.; Nakamichi, N.; Ikeda, J.; Kimura, H.; Aozasa, K., High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Exp. Cell Res., 2007, 313 (9), 1877-1885.
34. He, H.; Nilsson, C. L.; Emmett, M. R.; Marshall, A. G.; Kroes, R. A.; Moskal, J. R.; Ji, Y.; Colman, H.; Priebe, W.; Lang, F. F.; Conrad, C. A., Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. Journal of proteome research, 2010, 9 (5), 2098-2108.
35. Plumb, J. A.; Milroy, R.; Kaye, S. B., Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res., 1989, 49 (16), 4435-4440
36. Wang, P.; Henning, S. M.; Heber, D., Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PloS one, 2010, 5 (4), e10202
37. Marques-Gallego, P.; den Dulk, H.; Backendorf, C.; Brouwer, J.; Reedijk, J.; Burke, J. F., Accurate non-invasive image-based cytotoxicity assays for cultured cells. BMC Biotechnol, 2010, 10, 43.
38. Hirose, Y.; Berger, M. S.; Pieper, R.O., P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res., 2001, 61 (5), 1957-1963;
39. Nam, C.; Yamauchi, H.; Nakayama, H.; Doi, K., Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner. Neurotoxicol. Teratol., 2006, 28 (6), 664-672.
40. Quasthoff, S.; Hartung, H. P., Chemotherapy-induced peripheral neuropathy. J. Neurol., 2002, 249 (1), 9-17
41. Xiao, W. H.; Bennett, G. J., Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain, 2008, 135 (3), 262-270
42. Ahles, T. A.; Saykin, A. J., Candidate mechanisms for chemotherapy-induced cognitive changes. Nature reviews. Cancer, 2007, 7 (3), 192-201
43. Mustafa, S.; Walker, A.; Bennett, G.; Wigmore, P.M., 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur. J. Neurosci., 2008, 28 (2), 323-330.
44. Gabella, G., Ultrastructure of the nerve plexuses of the mammalian intestine: the enteric glial cells. Neuroscience, 1981, 6 (3), 425-436.
45. Sasselli, V.; Pachnis, V.; Burns, A. J., The enteric nervous system. Dev. Biol., 2012, 366 (1), 64-73.
46. Lohr, L., Chemotherapy-induced nausea and vomiting. Cancer J, 2008, 14 (2), 85-93
47. Jordan, K.; Schmoll, H. J.; Aapro, M. S., Comparative activity of antiemetic drugs. Crit. Rev. Oncol. Hematol., 2007, 61 (2), 162-175.
48. Darmani, N. A., Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals, 2010, 3 (9), 2930-2955.